2016
Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes
Cain LE, Caniglia EC, Phillips A, Olson A, Muga R, Pérez-Hoyos S, Abgrall S, Costagliola D, Rubio R, Jarrín I, Bucher H, Fehr J, van Sighem A, Reiss P, Dabis F, Vandenhende MA, Logan R, Robins J, Sterne JAC, Justice A, Tate J, Touloumi G, Paparizos V, Esteve A, Casabona J, Seng R, Meyer L, Jose S, Sabin C, Hernán MA. Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes. Medicine 2016, 95: e5133. PMID: 27741139, PMCID: PMC5072966, DOI: 10.1097/md.0000000000005133.Peer-Reviewed Original ResearchConceptsCD4 cell countEfavirenz regimenVirologic failureVirologic outcomesSurvival differencesNucleoside reverse transcriptase inhibitor (NRTI) backboneCell countReverse transcriptase inhibitor backboneAtazanavir-containing regimensAIDS-free survivalHuman immunodeficiency virusImmune deficiency syndromeHIV-CAUSAL CollaborationAtazanavir regimenHazard ratioClinical outcomesImmunodeficiency virusProspective studyDeficiency syndromeMean changeRegimensEfavirenzTime-varying covariatesInhibitor backboneRegimen
2015
Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy
Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, Gill M, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, van Sighem A, Samji H, Hogg RS, Rybniker J, Sabin CA, Jose S, del Amo J, Moreno S, Rodríguez B, Cozzi-Lepri A, Boswell SL, Stephan C, Pérez-Hoyos S, Jarrin I, Guest JL, Monforte A, Antinori A, Moore R, Campbell CN, Casabona J, Meyer L, Seng R, Phillips AN, Bucher HC, Egger M, Mugavero MJ, Haubrich R, Geng EH, Olson A, Eron JJ, Napravnik S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JA, Hernán MA, Systems A. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. International Journal Of Epidemiology 2015, 45: 2038-2049. PMID: 26721599, PMCID: PMC5841611, DOI: 10.1093/ije/dyv295.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyCopies/Antiretroviral Therapy Cohort CollaborationTime-varying covariatesTight control groupAdjusted hazard ratioAntiretroviral therapy regimenAIDS Research NetworkIntegrated Clinical SystemsHIV-CAUSAL CollaborationDeath eventsCohort CollaborationHazard ratioTherapy regimenRandomized trialsInverse probability weightingInclusion criteriaMortality analysisClinical treatmentAIDSTherapyDeath analysisDeathTrialsComparative effects